The study included 1848 diffuse large B-cell lymphoma (DLBCL)patients treated with chemotherapy/rituximab. The aims were to validate the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and explore the effect of adding high Beta-2 microglobulin (b2M), primary extranodal presentation and intense treatment to the NCCN-IPI variables in order to develop an improved index. Comparing survival curves, NCCN-IPI discriminated better than IPI, separating four risk groups with 5-year overall survival rates of 93%, 83%, 67% and 49%, but failing to identify a true high-risk population. For the second aim the series was split into training and validation cohorts: in the former the multivariate model identified age, lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, Stage III-IV, and b2M as independently significant, whereas the NCCN-IPI-selected extranodal sites, primary extranodal presentation and intense treatments were not. These results were confirmed in the validation cohort. The Grupo Español de Linfomas/Trasplante de M edula osea (GELTAMO)-IPI developed here, with 7 points, significantly separated four risk groups (0, 1-3, 4 or ≥5 points) with 11%, 58%, 17% and 14% of patients, and 5-year overall survival rates of 93%, 79%, 66% and 39%, respectively. In the comparison GELTAMO IPI discriminated better than the NCCN-IPI. In conclusion, GELTAMO-IPI is more accurate than the NCCN-IPI and has statistical and practical advantages in that the better discrimination identifies an authentic high-risk group and is not influenced by primary extranodal presentation or treatments of different intensity.
The International Prognostic Index (IPI), established in 1993 for patients with aggressive non-Hodgkin lymphoma, identified five clinical factors of independent prognostic value for survival (Table I) , and their combination separated four risk groups, low (LR), low-intermediate (LIR), high-intermediate (HIR) and high (HR), with significantly different 5-year overall survival (5-year OS) rates of 73%, 51%, 43% and 26%, respectively (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993) . The IPI proved to be of easy and universal use and has been the standard practical prognostic tool for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.
However, in reality, the concepts of DLBCL as an entity and the means by which it is managed have changed considerably over the years. New histological, immunohistochemical and cytogenetic concepts, which seem to reflect biological facts, have allowed more accurate subtyping and classification of DLBCL, and have occasioned two updates of the World Health Organization classification (Jaffe et al, 2001; Swerdlow et al, 2008 Swerdlow et al, , 2016 . Also, the use of more intense treatments b2M, b 2 -microglobulin; GELTAMO, Grupo Español de Linfomas y Trasplantes de M edula osea; IPI, international prognostic index; LDH, lactate dehydrogenase; NA, not applicable; NCCN, National Comprehensive Cancer Network. *Normalized: Relationship between individual and normal local laboratory values: normal, high (>1) and high (>3).
†Extranodal involvement of bone marrow, central nervous system, liver/gastrointestinal tract, or lung.
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and the availability of anti-CD20 antibodies, mainly rituximab, have improved the outcome of patients (Coiffier et al, 2002; Habermann et al, 2006) . To try to determine the influence of these changes on the prognostic effect of the IPI, the British Columbia Cancer Agency (BCCA) evaluated patients treated with rituximab and CHOP (doxorubicin, cyclophosphamide, vincristine and prednisone), and concluded that a more convenient grouping of the risk factors, the revised IPI (R-IPI), yielded three significantly distinct risk groups (Sehn et al, 2007) , but failed to identify patients with a very bad outcome, as even its HR group has a 5-year OS of 55%. In a study of 1062 patients from three prospective German trials (Ziepert et al, 2010) , the IPI showed predictive value with different treatment intensities (CHOP and a dose-escalated regimen), with or without rituximab and in patients older and younger than 60 years; all the factors included in the IPI, except for the involvement of more than one extranodal site, maintained their predictive value, but the IPI failed to identify a group with a 3-year overall survival (OS) rate of less than 50%. On the other hand, the inclusion in the prognostic models of the biomarkers and genes identified from the immunohistochemical and expression profile studies as being involved in DLBCL biology has not significantly improved the effectiveness of the IPI, which uses only standard clinical parameters (Salles et al, 2011; Hong et al, 2013) . To improve the prognostic power of the IPI, data from 1650 DLBCL patients treated with rituximab and chemotherapy in seven National Comprehensive Cancer Network (NCCN) cancer centres were assessed and a prognostic score developed (Zhou et al, 2014) . The five predictor variables included were age (3 levels), normalized serum lactate dehydrogenase (LDH; 2 levels), Ann Arbor stage III-IV, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2, and a group of distinct extranodal involvement sites (bone marrow, central nervous system (CNS), liver, gastrointestinal tract, and lung). This gave rise to the NCCN-IPI, with a maximum score of 8 points (Table I) , which determined four risk groups with significantly different 5-year OS. The NCCN-IPI improved the discrimination of the LR and HR groups with, respectively, 96% and 33% of 5-year OS rates, and was validated in an independent series of 1138 patients from the BCCA and also in an Austrian series of 499 patients treated with R-CHOP (Melchardt et al, 2015) . However, a population-based Danish/Canadian series of 434 patients staged with positron emission tomography/ computed tomography (PET/CT) (El-Galaly et al, 2015) was not able to reproduce the NCCN-IPI exactly, and although it distinguished four risk groups it did not identify a very highrisk group. The aims of the present study were, first, to validate the prognostic efficacy of the NCCN-IPI in a large multicentre nationwide series of patients with DLBCL in Spain, and, second, to explore the possible effect of adding to the previous three new variables and to derive a modified score [the Grupo Español de Linfomas/Trasplante de M edula osea (GELTAMO)-IPI] that would improve the accuracy of NCCN-IPI.
Methods

Patients and endpoints
The files of 2156 patients with DLBCL were retrieved from the archives of 20 academic and community hospitals in the GELTAMO network in Spain. The patients contributed by the participating centres were not in any way selected by previous criteria; the only condition for incorporation into the study was that they fulfilled the inclusion criteria, and had no other characteristic that might have biased the selection. Although some patients were enrolled in trials in large hospitals, the centres provided the patients irrespective of such involvement. The study was coordinated and the analysis centralized in the MD Anderson Cancer Centre, Madrid, Spain. All the files were reviewed and, after cleaning the data of each case in the original databases, the final series consisted of 1848 patients with the complete data required for the different analyses. Data were missing at random and independent of outcomes, so there was no intentional bias in the selection. Patients were only excluded on the grounds of unavailability of data. A diagnosis of DLBCL was established in the initial lymph node biopsy or in a biopsy from primary extranodal site by local haematopathologists in the contributing centres. Inclusion criteria were: patient age ≥18 years, with de novo diagnosis of DLBCL treated with curative intent with the combination of rituximab and doxorubicin-containing chemotherapy. All histological subtypes of DLBCL and patients positive for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) were also eligible; cases with primary nodal and primary extranodal presentation were eligible, but primary testicular and central nervous system (CNS) were not. Treatments with R-CHOP and with more intense than R-CHOP protocols were acceptable, but treatments of non-curative intent with shorter (less than 6 cycles) or lower doses (mini-R-CHOP or similar dose reductions), or non-adriamycin-containing combinations were not acceptable. The presence of a concomitant or previous tumour in the previous 5 years was also an exclusion criterion. Patients were diagnosed between January 1998 and July 2014, with a minimum follow-up of 1 year.
The baseline clinical characteristics, registered at the time of diagnosis, were age, sex, Ann Arbor stage, LDH and b2M serum levels, B symptoms and ECOG PS. LDH and b2M levels were normalized and categorized as normal (ratio of result to the normal level in the local laboratory ≤1) or high (ratio >1). Primary nodal or extranodal presentation and the number and site of specific extranodal involvement were recorded.
Complete remission (CR) was accepted after the resolution of all lymph nodal and extranodal involvement based on image techniques (CT in all cases, although PET/computed axial tomography (CAT) may have been used in some patients) and, when accessible, on a biopsy of previously affected extranodal areas. The primary endpoint was OS at 5 years (5-year OS), defined as the time from diagnosis to death from any cause, as was the case in the IPI (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993) and NCCN-IPI studies (Zhou et al, 2014) .
This study was approved by the Ethics Committee (EC) of the Hospital Ram on y Cajal (Madrid, Spain), which is the reference EC.
Statistical analysis
Validation of NCCN-IPI. Risk groups and variables were as described in the NCCN-IPI: age (>40 to ≤60; >60 to ≤75; >75 years), normalized LDH serum levels (>1 to ≤3, >3), Ann Arbor stage III-IV, extranodal disease (involvement of distinct sites, bone marrow, CNS, gastrointestinal tract, liver or lung), and PS ≥2 (Table I) . Likewise, variables included in the IPI score (age >60 years, normalized LDH ≥1, PS ≥2, Stage III-IV, ≥2 sites of extranodal involvement) were used to determine risk groups and survival curves.
Development of the GELTAMO-IPI. To develop the GEL-TAMO-IPI, the series was split into training and validation cohorts, as close as possible to the usual two-thirds and onethird proportion, on the basis of the correlative codes of the participating centres. This non-random splitting reduces the similarity of the two sets of patients and tends to avoid overoptimistic results in the validation (Altman et al, 2009 ). The training set was used to derive the model using univariate and multivariate Cox regression OS models. All the variables in the NCCN-IPI and three new variables (b2M, treatments more intense than R-CHOP, and primary extranodal presentation) were included.
No other standard analytical or clinical parameters were explored in the models, as they had not shown significance in the IPI (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993). Albumin serum levels or other newer interesting prognostic factors, such as the counts and proportion of lymphocytes and monocytes or elevated serum free light chains, were not assessed in the model because there were not sufficient data available. As mentioned above, immunohistochemical and molecular markers have not significantly improved the effectiveness of the IPI (Salles et al, 2011; Hong et al, 2013) and have not been included in the models.
To minimize the loss of patients from the multivariate analyses, at each step of the backward elimination strategy, cases with missing values for the newly eliminated variable were incorporated into the model, after ensuring that this did not produce substantial changes in the model coefficients. The linearity assumption of age, LDH and b2M as continuous variables with respect to their effects on survival was visually checked using Martingale residuals (Cleves et al, 2008) and categorized accordingly.
The validation set was used to assess the predictive accuracy of the resulting model by estimating the survival curves for the groups of patients.
Comparisons of the NCCN-IPI, IPI and GELTAMO IPI
The scores were compared using patients with complete data for each comparison: NCCN-IPI vs. IPI (1797 patients) and GELTAMO IPI vs. NCCN-IPI (1672 patients). The scores were compared using the reclassification calibration statistic, i.e., the Hosmer-Lemeshow goodness-of-fit (as indicated by the P-value) applied to reclassified categories. This test compares the proportions of patients whose estimated risk shifts in the correct and wrong directions on the basis of a chi-square goodness-of-fit test within reclassified categories for each score separately. In this context, a statistically significant P-value indicates a poor fit (Cook & Ridker, 2009 ).
All survival curves were obtained by the Kaplan-Meier method, and compared using the log-rank test. In all analyses, values of P < 0Á05 were considered statistically significant, unless otherwise specified. Statistical analyses were carried out with Stata 14.0 (StataCorp, College Station, TX, USA).
Results
Patients
The general characteristics of the series are summarized in Table SI . The median follow-up of the censored patients was 57 months.
Extranodal involvement after initial diagnosis of DLBCL in a lymph node was accepted on the basis of the image findings or eventually by biopsy; bone-marrow involvement always required biopsy confirmation and secondary CNS involvement was concluded when confirmed by tumour biopsy or cerebrospinal fluid cytology. Primary extranodal lymphoma presentation was defined when an extranodal site was involved without dominant nodal involvement demonstrated by image, independently of stage. The primary extranodal lymphoma presentation always required histological diagnosis in the affected site. Primary testicular and CNS required a different treatment approach and those cases were not acceptable for the study. Spleen involvement was not considered as extranodal. The majority (91Á9%) of chemotherapy protocols were CHOP or CHOP-like variants (with liposomal doxorubicin), but more intense than R-CHOP combinations [R-EPOCH (doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone) , R-MegaCHOP (CHOP with cyclophosphamide 1500 mg/m 2 and doxorubicin 65 mg/m 2 ) (Pardal et al, 2014) or the eventual addition of bortezomib or lenalidomide to CHOP] were also 
Validation of NCCN-IPI
Of the total of 1848 patients, 1777 cases had complete data for all the variables required to calculate the NCCN-IPI. The demographic and clinical characteristics of the patients in the present study and those in the NCCN and BCCA series (Zhou et al, 2014) are shown in Table II . The clinical features of the patients in the present series were intermediate between those of the NCCN and BCCA series; the major difference between the GELTAMO and NCCN series was that the former had a higher proportion of patients with PS ≥2 (30% vs. 11%, respectively). There were minor differences in the rest of the variables. With respect to differences from the BCCA series, the GELTAMO series only had a higher proportion of extranodal involvement (25% vs. 41%, respectively). The percentages of patients in the LR, LIR, HIR and HR risk groups were 13%, 35%, 37% and 16%, respectively (Table III) , and were similar to those in the NCCN series, except for a higher percentage of patients in the HR group (16% vs. 8%). The four risk groups had 5-year OS rates of 93%, 83%, 67% and 49%, respectively, with significant differences in the global and pairwise comparisons (P < 0Á001, all comparisons) (Fig 1A) . The NCCN-IPI separated the present series into four risk groups and identified a very good outcome group, but failed to identify a group of patients with a 5-year OS substantially less than 50% (the actual value was 49%), whereas in the NCCN series, the HR group had an estimated poor prognosis with a 5-year OS rate of 33%.
Evaluation of the IPI
A total of 1764 patients had complete data for the calculation of the IPI, which also identified four risk groups with similar proportions of patients to those in the NCCN series (Table III) . The 5-year OS rates for the LR, LIR, HIR and HR were also similar, at 88%, 77%, 68% and 51%, respectively, but they were significantly different in the global (P < 0Á001) and paired comparisons (LR vs. LIR, P < 0Á001; LIR vs. HIR, P < 0Á009; HIR vs. HR, P < 0Á001) (Fig 1B) . The IPI also failed to identify a group of very poor outcome patients with a 5-year OS less than 50%.
Development of the GELTAMO-IPI
From the series of 1848 patients, the resulting training and validation cohorts consisted of 1230 and 618 patients (348 and 161 deaths, and 55 and 59 months of follow-up of the censored patients), respectively (Table SII) . Univariate analysis of the training cohort showed all the variables to be significant, except the use of a more intense treatment than R-CHOP (Table IV) . The effect of age, as a continuous variable, on survival was not linear, with changes in the slope after 65 and 79 years. The effects of normalized LDH and b2M were not linear either, with changes in the slope with values of >1-3 and >3. The effect of the PS changed for values of >2 and ≥3. Therefore, in the multivariate Cox regression model, age was stratified into three groups (18-64, 65-79 and ≥80 years); Stage in two groups (I-II and III-IV) groups; PS in three groups (0-1, 2, and 3-4); and normalized b2M and LDH in three groups (normal value, >1 and >3); all the variables, except for primary extranodal presentation and extranodal involvement in the NCCN-IPI selected sites, had an independent prognostic effect ( Table IV) . The two high levels of normalized b2M had similar hazard ratios, which did not justify the separation of the groups, so they were combined into a single category (high, >1). This also happened with LDH. After rounding up the hazard ratios of the significant variables, a maximum score of 7 points was obtained (Table I) . Risk groups were defined by comparing the risk for 5-year OS in patients with each possible number of factors (1-7) and combining groups with similar risk, determined from the similarity of the Kaplan-Meier curves. This resulted in four risk groups being established: LR (0 points), LIR (1-3 points), HIR (4 points) and HR (≥5 points) (Table III) . These groups included 12%, 57%, 18% and 13% of the patients, respectively, with 5-year OS rates of 93%, 79%, 66% and 44% (Table SIII) , which were significantly different (P < 0Á001) in the global and all pairwise comparisons (Fig 2A) . The score also identified the four risk groups with statistically significantly different 5-year OS in the validation cohort (P < 0Á05 in the global and all pairwise comparisons) (Fig 2B) .
When the whole series was considered, the GELTAMO-IPI separated the four risk groups with significantly different 5-year OS rates of 93%, 79%, 66% and 39% (P < 0Á001 in all comparisons) (Table III and Fig 2C) ; the NCCN-IPI also significantly separated the four risk groups with 5-year OS rates 93%, 83%, 67% and 49% (Table III) . Both scores identified a low risk prognostic group with a 5-year OS rate of 93%, but GELTAMO-IPI showed better discrimination for the HR group than NCCN-IPI (5-year OS of 39% vs. 49%) ( Table III) .
The comparison of the NCCN-IPI and IPI is shown in Table V . As an example, in the LIR group of 360 patients with an 85% 5-year OS observed survival, the IPI classification placed them in a group with 88% 5-year OS, whereas the NCCN-IPI reclassified them into a group with 84% 5-year OS, closer and therefore better to the true value of 85% 5-year OS. As for the reclassification calibration statistic, a significant P-value indicates poor fit. Here, the test for IPI (v 2 = 17Á26; P = 0Á016) showed a lack of fit, while that for NCCN-IPI (v 2 = 13Á12; P = 0Á069) gave a better fit, indicating that the NCCN-IPI has better risk assessment.
For the comparison of the GELTAMO-IPI and the NCCN-IPI, the reclassification is shown in Table VI . Here, for example, in the case of the 166 patients of the HR group with an observed 5-year OS of 41%, the NCCN-IPI placed them in a group with 49% 5-year OS, whereas the GEL-TAMO-IPI reclassified them into a group with 39% 5-year OS, which is closer to the true value of 41%. The results of the tests (GELTAMO-IPI: v 2 = 9Á54; P = 0Á299; NCCN-IPI: v 2 = 16Á40; P = 0Á037) indicate that the GELTAMO-IPI provides better discrimination.
Discussion
The present study confirms the efficacy of the NCCN-IPI at separating risk groups for survival in a large independent series of patients with DLBCL in Spain. Patients were unselected, were not systematically included in trials, were recruited from academic hospitals and smaller community hospitals and, as a whole, were more similar to those of the . Global comparison P < 0Á001; LR vs. LIR P < 0Á001; LIR vs HIR P < 0Á001; HIR vs. HR P < 0Á001. (B) IPI (1764 patients). Global comparison P < 0Á001; LR vs. LIR P < 0Á001; LIR vs. HIR P < 0Á009; HIR vs. HR P < 0Á001.
BCCA series with respect to their characteristics and aggressiveness. Although the sample was not population-based, it did represent a real-life population of patients with DLBCL. Compared with the NCCN series, the present series contained a higher proportion of patients with PS ≥2 and a higher proportion of patients in the HR group, indicating that it featured more patients with more aggressive disease. Despite this, the most important discrepancy was that the HR group had a 5-year OS of 49%. The very poor outcome group that in the NCCN series had a 33% rate of 5-year OS could not be reproduced. In the present series the IPI also significantly separated groups with different 5-year OS rates, but, as was the case in the NCCN (Zhou et al, 2014) and in the German series (Ziepert et al, 2010) , it also failed to identify a subset with very poor prognosis.
In our series, the comparisons between NCCN-IPI and IPI with the reclassification calibration statistics indicated that NCCN-IPI had better discriminatory power. This was also the case in the Austrian series (Melchardt et al, 2015) , in which the NCCN-IPI has been validated, showing a better 
b2M, b 2 -microglobulin; 95% CI, 95% confidence interval; HR, Hazard ratio; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; R-CHOP, rituximab; doxorubicin, cyclophosphamide, vincristine and prednisone; NCCN, National Comprehensive Cancer Network. *Number of patients with available data in each category. †Percentage of patients with a positive finding in each category. ‡Normalized. Training Series (n = 1085 patients). Global comparison P < 0Á001; LR vs. LIR P < 0Á001; LIR vs. HIR P < 0Á001; HIR vs. HR P < 0Á001. (B) GELTAMO-IPI. Validation cohort (n = 587 patients). Global comparison P < 0Á001; LR vs. LIR P = 0Á022; LIR vs. HIR P = 0Á002; HIR vs. HR P < 0Á001. (C) GELTAMO-IPI. Final database (n = 1672). Global comparison P < 0Á001; LR vs. LIR P < 0Á001; LIR vs. HIR P < 0Á001; HIR vs. HR P < 0Á001.
discriminatory capacity than the IPI and identifying a very bad outcome group with a 5-year OS of 32Á3%. However, the IPI also separated the high-risk group with a 5-year OS rate of 40%. On the other hand, in the study by El-Galaly et al (2015) , the NCCN-IP separated significant risk groups, but failed to identify a genuine very high-risk group. The GELTAMO-IPI separated four risk groups with significantly different 5-year OS and had a better discriminatory capacity than the NCCN-IPI. The GELTAMO-IPI was able to identify a poor-outcome group with 5-year OS of 39%, which was not possible with either the NCCN-IPI or the IPI. This HR group represents only a small proportion of patients (14%), but it is similar to that identified by the NCCN-IPI in the GELTAMO series (16%) and even higher than in the original NCCN series (only 8%) ( Table III) .
The inclusion of the new variables is not arbitrary, but due to the fact that they are most clinically relevant in practice and whose potential prognostic influence has not been evaluated in the context of IPI or NCCN-IPI. b2M has been a classic prognostic factor in the pre-rituximab (Rodriguez et al, 1992; Johnson et al, 1993) and post-rituximab (Seo et al, 2014; Miyashita et al, 2015) eras, but in the IPI study, information on b2M levels was available for only 215 (6%) of the patients, and although it was of significant influence in the univariate analysis, it was not considered in the multivariate model. b2M was not included in the NCCN-IPI score work-up analyses (Zhou et al, 2014) , either. However, this was not due to statistical considerations, but because it was not among the reported variables and because data were not available for the analysis. Only recently, in an Austrian series a subset of 224 patients that had b2M determinations, a high level of b2M (and also a low level of serum albumin) had an adverse prognostic effect on survival that was independent of the NCCN-IPI score when stratified as low-versus high-level groups. However, most probably because the data were scarce, b2M was not included in multivariate models with the other individual variables to test its independent effect (Melchardt et al, 2015) .
The possible effect of more intense than R-CHOP treatment has been explored in the present study, considering that the German study included treatments with R-CHOP and also with a dose-escalated regimen (cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, Mega-CHOEP) (Ziepert et al, 2010) . Furthermore, whereas in the BCCA validation series all patients had received R-CHOP, the treatments in the original NCCN series (Kho et al, 2008; Zhou et al, 2014) , despite being collected in the rituximab era, were not specified. However, the series included patients from trials in seven cancer centres that had very probably received different intensity chemotherapy treatments (Ziepert et al, 2010) .
Primary extranodal presentation was included as a variable because this had not been addressed by the IPI, R-IPI, or NCCN-IPI. On the other hand, the specific prognostic influence of extranodal dissemination is controversial, with discordant data in different studies. The involvement of ≥1 extranodal involvement was not significant in any of the NCCN series (Zhou et al, 2014) , the German study (Habermann et al, 2006) , or a Danish study of 1990 patients (Gang et al, 2015) . Conversely, in the Danish-Canadian series (El-Galaly et al, 2015) , which identified extranodal involvement with PET/CT, the number of involved extranodal sites was strongly correlated with the prognosis, indicating that the involvement of >2 extranodal sites seems to be a better cut-off than the involvement of ≥1, as considered in the IPI, the involvement of >3 sites selects a very high-risk population, and modifying the scoring based on the number of involved sites improves the accuracy of the NCCN-IPI. The distinct extranodal involvement included in the NCCN-IPI is also controversial; the adverse prognostic effect of CNS involvement is well known, but that of bone-marrow : there are discrepancies concerning the prognostic effect of the bone marrow involvement, whereby it may be observed in the PET/CT or in the biopsy (El-Galaly et al, 2015) . In some studies, bone marrow involvement demonstrated by PET/CAT has been shown to have a similar prognostic effect to other extranodal sites (Khan et al, 2013) . In the NCCN-IPI study, genitourinary involvement was not prognostic, but was in another study (Lu et al, 2015) . The involvement of female genital organs was significant in another study (El-Galaly et al, 2015) , and the adverse effect of the primary testicular site is well known (Vitolo et al, 2011) . The effect of other extranodal involvement is not clearly established either, as primary and secondary involvement of the stomach and intestinal tract had a better outcome in some series (Raderer et al, 2002; Lopez-Guillermo et al, 2005; Takahashi et al, 2012) , contrary to the findings from the NCCN-IPI series. In a study of 1781 patients treated with R-CHOP, there were no differences in the outcome of patients with primary extranodal or primary nodal lymphoma, and no distinct extranodal site determined a worse outcome (Hui et al, 2010) . It has to be noted that, in the GELTAMO-IPI, primary extranodal presentation or treatment more intense than R-CHOP did not influence survival in the Cox models; although there were relatively few such patients (256 and 107, respectively), a HR of 0Á7 and 1, respectively, and the confidence intervals (Table IV) , strongly support their lack of statistically significant influence on survival; this indicates that the GELTAMO-IPI might be applied to patients with primary extranodal presentation and those treated with both R-CHOP or more intensive regimens.
In conclusion: (i) Our results validate the prognostic effect of the NCCN-IPI, which is more accurate than the IPI, but, contrary to the results in the original publication, fails to identify a real high-risk DLBCL group. (ii) The addition of b2M to the NCCN-IPI variables results in the GELTAMO-IPI, that has several statistical and practical advantages: it has better discrimination than the NCCN-IPI; it can identify an authentic HR group with a 5-year OS rate less than 50%; and it is not affected by either primary extranodal presentation or treatments more intense than R-CHOP.
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